Michael Earing is a Cardiology physician. OpenAlex indexes 131 publications with 6,034 citations (h-index 39); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Cardiology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
888-824-0200Provider last certified this registry record 29 Jul 2022.
Clinical trials
- Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury
Sponsor: Medical College of Wisconsin
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.3%Beta blocker16.1%Metoprolol Succinate77%Metoprolol Tartrate23%Part D<11 patientsEndothelin Receptor Antagonist14.6%Opsumit75%Ambrisentan26%Part D<11 patients+ 5 more classes in this area
Blood & clotting
14.9%Vitamin K antagonist7.4%Warfarin Sodium100%Part D<11 patientsFactor Xa inhibitor4%Xarelto100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
8%Phosphodiesterase 5 Inhibitor8%Sildenafil Citrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Outcomes of Adult Fontan-Associated Liver Disease and Combined Heart-Liver Transplantation
Journal of the American College of Cardiology
2023 - Morbidity and Mortality in Adult Fontan Patients After Heart or Combined Heart-Liver Transplantation
Journal of the American College of Cardiology
2023 - Neurocognitive Impairment and Its Long-term Impact on Adults With Congenital Heart Disease
Progress in Cardiovascular Diseases
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”